BerandaPRRUF • OTCMKTS
add
Immutep Ltd
Tutup sebelumnya
$0,18
Rentang tahun
$0,17 - $0,28
Kapitalisasi pasar
292,16Â jt USD
Volume Rata-Rata
500,00
Rasio P/E
-
Hasil dividen
-
Bursa utama
ASX
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (AUD) | Des 2023info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 1,06Â jt | 25,23% |
Biaya operasional | 2,40Â jt | 16,20% |
Laba bersih | -10,61Â jt | -2,93% |
Margin laba bersih | -1,01Â rb | 17,80% |
Penghasilan per saham | — | — |
EBITDA | -11,10Â jt | -8,28% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (AUD) | Des 2023info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 103,73Â jt | 51,71% |
Total aset | 123,79Â jt | 43,92% |
Total liabilitas | 8,15Â jt | -12,60% |
Total ekuitas | 115,64 jt | — |
Saham yang beredar | 1,19 M | — |
Harga terhadap reservasi | 1,83 | — |
Tingkat pengembalian aset | -23,35% | — |
Pengembalian modal | -24,65% | — |
Arus Kas
Perubahan bersih tunai
| (AUD) | Des 2023info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -10,61Â jt | -2,93% |
Kas dari operasi | -9,23Â jt | -54,83% |
Tunai dari investasi | -209,56Â rb | -607,90% |
Tunai dari pembiayaan | -215,93Â rb | -278,22% |
Perubahan bersih tunai | -9,84Â jt | -69,40% |
Arus kas bebas | -6,90Â jt | -2,37% |
Tentang
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
CEO
Didirikan
2001
Situs
Karyawan
19
